1. Jersey Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Integrated Diagnostics Holdings plc

Integrated Diagnostics Holdings plc

IDHC.L
Integrated Diagnostics Holdings plcGB flagLondon Stock Exchange
0.50
USD
-0.01
- -
291.83MMarket Cap
Integrated Diagnostics Holdings plc
IDHC.L
(London Stock Exchange)

Recent

price

0.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
1.12
1.43
1.69
1.95
2.52
3.2
3.71
4.43
8.71
6.01
6.87
9.64
13.51
7.91
Revenue per Share
- -
0.1
0.22
0.24
0.43
0.62
0.84
0.85
0.99
2.35
0.9
0.85
1.82
2.17
1.36
Basic EPS, GAAP
- -
0.31
0.38
0.22
0.58
0.41
0.37
0.8
1.26
3.34
-0.17
0.36
2.26
2.38
1.01
Free Cash Flow per Basic Share
- -
0.45
0.39
0.01
0.15
0.63
0.72
0.75
0.75
0.8
2.35
- -
0.05
0.92
- -
Dividend per Share
- -
-0.31
1.79
2.03
2.31
2.31
2.45
2.55
2.79
4.37
3.09
3.92
4.8
6.25
4.81
Book Value per Share
- -
0.41
0.33
0.56
1.08
1.09
1.21
1.17
1.28
1.89
1.24
2.32
2.85
3.92
2.95
Tangible Book Value per Share
- -
600
600
600
600
600
600
600
600
600
600
600
594
581
600
Basic Weighted Avg Shares
- -
672
860
1,015
1,171
1,514
1,921
2,226
2,656
5,225
3,605
4,123
5,720
7,855
4,748
Sales/Revenue/Turnover
- -
20.88
30.14
27.91
40.09
36.05
36.15
35.91
38.69
43.77
24.21
19.17
21.22
27.05
20.08
Operating Margin (%)
- -
145
116
36
45
62
77
153
185
239
317
401
483
565
438
Depreciation Expense
- -
62
133
145
260
374
502
511
594
1,413
541
510
1,077
1,262
817
Net Income, GAAP
- -
50.6
42.7
43.54
31.3
31.28
30.73
33.45
37.11
33.14
38.31
36.48
29.95
38.56
33.88
Effective Tax Rate (%)
- -
9.25
15.43
14.28
22.24
24.7
26.13
22.95
22.36
27.04
15.01
12.38
18.84
16.07
17.21
Profit Margin (%)
191
188
129
198
498
494
386
210
351
694
160
687
916
1,254
1,010
Working Capital
2
1
1
60
120
139
167
358
466
722
1,008
959
1,011
1,195
1,013
LT Debt
2,069
1,946
1,805
1,942
2,299
2,314
2,401
2,360
2,426
2,794
2,447
3,101
3,499
4,130
3,552
Total Equity
- -
3.35
7.55
7.94
13.78
14.52
17.86
18.41
21.02
42.33
13.97
12.8
18.24
23.42
15.68
Return on Invested Capital (%)
- -
-70.65
25.55
11.26
17.71
23
29.93
28.35
27.59
46.01
17.98
17.64
27.92
24.32
26.6
Return on Capital (%)
- -
- -
- -
12.67
20.01
26.94
35.14
34.08
37.07
65.71
24.16
24.25
41.4
38.91
32.94
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
ST Debt
220
271
261
LT Borrowings
67
54
54
LT Finance Leases
891
966
959
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
600
600
600
Market Capitalization
6,669
11,449
9,006

Working Capital

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
Total Current Assets
1,962
2,371
2,717
Cash, Cash Equivalents & STI
861
984
1,294
Accounts Receivable, Net
570
703
753
Inventories
375
480
462
Total Current Liabilities
1,275
1,574
1,707
Payables & Accruals
- -
- -
- -
ST Debt
220
271
261
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.42%
12.07%
18.03%
Free Cash Flow
55.5%
52.58%
2.93%
Net Income, GAAP
37.43%
39.74%
17.15%
Sales/Revenue/Turnover
26.29%
31.22%
37.34%
Total Cash Common Dividend
- -
- -
1,851.58%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,171
1,327
- -
- -
5,720
2025
1,583
- -
- -
- -
7,855
2026
2,073
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.7
- -
- -
- -
1.82
2025
0.42
- -
- -
- -
2.17
2026
0.75
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.05
2025
- -
- -
- -
- -
0.92
2026
- -
- -
- -
- -
- -
Similar Companies
Joinn Laboratories(China)Co.,Ltd. (6127.HK)
Interpace Biosciences, Inc. (IDXG)
Invitae Corporation (NVTAQ)
BIONET Corp. (1784.TWO)
Genetics Generation Advancement Corp. (4160.TWO)
IDL Diagnostics AB (publ) (IDLDX.ST)
Business
Integrated Diagnostics Holdings plc (IDH) is a leading woman-led consumer healthcare company that provides fully integrated medical diagnostic services across the Middle East and Africa. The company offers over 3,000 pathology tests encompassing immunology, microbiology, haematology, endocrinology, clinical chemistry, molecular biology, histopathology, cytogenetics, and genetics testing; radiology services including basic imaging, nuclear medicine, ultrasound, and radiotherapy; and molecular diagnostics for conditions such as hepatitis and diabetes glucose testing, delivered through its hub-spoke-spike model with over 600 branches. IDH operates core brands Al Borg and Al Borg Scan in Egypt, Al Mokhtabar in Egypt and Sudan, Biolab in Jordan and Saudi Arabia, Ultralab in Sudan, and Echo-Lab in Nigeria, primarily serving walk-in patients and contract segments with a focus on underserved markets. Founded in 2008 through the acquisition of Al Borg Laboratories (established 1990) and headquartered in Cairo, Egypt, IDH generates the majority of its revenue from Egypt while expanding regionally. Recent developments include the full acquisition of Biolab KSA in December 2024 by purchasing the remaining 49% stake for USD 3.2 million, bringing its ownership to 100%; the June 2025 acquisition of Cairo Ray for Radiotherapy by Al Borg, enhancing its Egyptian radiology portfolio; delisting from the Egyptian Exchange in 2024 to streamline operations on the London Stock Exchange; and strong financial performance with EGP 5.7 billion in 2024 revenue and 42% growth in first-half 2025.